<DOC>
	<DOCNO>NCT01327053</DOCNO>
	<brief_summary>This study ass efficacy safety oral treatment two dose level LDE225 patient locally advance metastatic BCC .</brief_summary>
	<brief_title>A Phase II Study Efficacy Safety Patients With Locally Advanced Metastatic Basal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Basal Cell</mesh_term>
	<criteria>Patients locally advance BCC metastatic BCC Patients adequate bone marrow , liver , renal function Patients major surgery within 4 week initiation study medication Patients unable take oral drug lack physical integrity upper gastrointestinal tract , know malabsorption syndrome . Patients concurrent medical condition may interfere potentially affect interpretation study . Patients neuromuscular disorder concurrent treatment drug may cause muscle damage . Patients concurrent therapy antineoplastic agent . Patients take part experimental drug within 4 week initiation study medication . Pregnant nursing ( lactate ) woman Women child bear potential unwilling use 2 form highly effective contraception throughout study 3 month last treatment Fertile male willing use condom throughout study 3 month last treatment . Patients unwilling unable comply protocol . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>locally advanced basal cell carcinoma ,</keyword>
	<keyword>metastatic basal cell carcinoma</keyword>
</DOC>